{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:34:10Z","timestamp":1772998450109,"version":"3.50.1"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid. Not all available urate-lowering therapies are equally effective and safe for use in patients with renal disease. The objective of this post-hoc analysis was to determine the effectiveness of the xanthine oxidase inhibitor febuxostat in reducing serum urate (sUA) levels in gouty patients who were either overproducers or underexcretors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Gouty subjects 18 to 85 years of age with sUA \u2265 8.0 mg\/dl at baseline were enrolled in a Phase 2, 28-day, multicenter, randomized, double-blind, placebo-controlled trial and randomized to receive febuxostat 40 mg, 80 mg, or 120 mg daily, or placebo. The primary efficacy endpoint was the proportion of subjects with sUA &lt; 6.0 mg\/dl at Day 28. Secondary efficacy endpoints included percentage reductions in sUA and urinary uric acid (uUA) from baseline to Day 28.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of the 153 subjects, 118 (77%) were underexcretors (uUA \u2264 800 mg\/24 h) and 32 (21%) were overproducers (uUA &gt; 800 mg\/24 h); baseline uUA data were missing for 3 subjects. Treatment with febuxostat led to the majority of subjects achieving sUA &lt; 6.0 mg\/dl at Day 28. Treatment with any dose of febuxostat led to significantly greater percentage reductions in uUA than that observed in the placebo group, for both underexcretors and overproducers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Febuxostat is a highly efficacious urate-lowering therapy in patients with gout regardless of overproduction or underexcretion status.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.101156","type":"journal-article","created":{"date-parts":[[2011,5,15]],"date-time":"2011-05-15T20:13:25Z","timestamp":1305490405000},"page":"1385-1389","source":"Crossref","is-referenced-by-count":39,"title":["Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors"],"prefix":"10.3899","volume":"38","author":[{"given":"DAVID S.","family":"GOLDFARB","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PATRICIA A.","family":"MacDONALD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BARBARA","family":"HUNT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LHANOO","family":"GUNAWARDHANA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2011,5,15]]},"reference":[{"key":"2018112909263829000_38.7.1385.1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f54d03"},{"key":"2018112909263829000_38.7.1385.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"2018112909263829000_38.7.1385.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x"},{"key":"2018112909263829000_38.7.1385.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"2018112909263829000_38.7.1385.5","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909263829000_38.7.1385.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"2018112909263829000_38.7.1385.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.23007"},{"key":"2018112909263829000_38.7.1385.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2018112909263829000_38.7.1385.9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","article-title":"Gout: six-year follow-up on probenecid (benemid) therapy","volume":"2","author":"Bartels","year":"1959","journal-title":"Arthritis Rheum"},{"key":"2018112909263829000_38.7.1385.10","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00003"},{"key":"2018112909263829000_38.7.1385.11","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0089-y"},{"key":"2018112909263829000_38.7.1385.12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2018112909263829000_38.7.1385.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"2018112909263829000_38.7.1385.14","unstructured":"Uloric\u00ae full prescribing information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc.; 2009."},{"key":"2018112909263829000_38.7.1385.15","unstructured":"European Medicines Agency . European Public Assessment Report for Adenuric. London: European Medicines Agency; 2010."},{"key":"2018112909263829000_38.7.1385.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"2018112909263829000_38.7.1385.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"2018112909263829000_38.7.1385.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"2018112909263829000_38.7.1385.19","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"2018112909263829000_38.7.1385.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076182"},{"key":"2018112909263829000_38.7.1385.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"2018112909263829000_38.7.1385.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"2018112909263829000_38.7.1385.23","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2018112909263829000_38.7.1385.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.10792"},{"key":"2018112909263829000_38.7.1385.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049023"},{"key":"2018112909263829000_38.7.1385.26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0272-6386(98)70067-8","article-title":"Regulation of renal urate excretion: a critical review","volume":"32","author":"Maesaka","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2018112909263829000_38.7.1385.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken460"},{"key":"2018112909263829000_38.7.1385.28","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"2018112909263829000_38.7.1385.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"key":"2018112909263829000_38.7.1385.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken457"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.101156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T12:59:38Z","timestamp":1543496378000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.101156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,15]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.3899\/jrheum.101156"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.101156","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,15]]}}}